SIM
CRBP icon

Studio Investment Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Studio Investment Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9
Closed -$107 – 323
2024
Q4 		$107 Hold
9
– – ﹤0.01% 320
2024
Q3 		$186 Hold
9
– – ﹤0.01% 285
2024
Q2 		$407 Hold
9
– – ﹤0.01% 285
2024
Q1 		$353 Hold
9
– – ﹤0.01% 260
2023
Q4 		$55 Hold
9
– – ﹤0.01% 241
2023
Q3 		$61 Hold
9
– – ﹤0.01% 231
2023
Q2 		$71 Hold
9
– – ﹤0.01% 219
2023
Q1 		$65 Sell
9
-1
-10% -$4 ﹤0.01% 221
2022
Q4 		$32 Hold
10
– – ﹤0.01% 197
2022
Q3 		$48 Hold
10
– – ﹤0.01% 166
2022
Q2 		$0 Buy
+10
New +$97 ﹤0.01% 189

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Studio Investment Management's CRBP Position: Q1 2025 in Review

Studio Investment Management sold out of Corbus Pharmaceuticals (CRBP) in Q1 2025, closing a stake of 9 shares — an estimated $107 sold.

Studio Investment Management first reported a position in CRBP in Q2 2022 and held it in 11 quarters. The position peaked at $407 in Q2 2024. 86 funds tracked by Wall St. Rank hold CRBP as of Q1 2025.

  • Studio Investment Management reported no remaining Corbus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Studio Investment Management sold 9 Corbus Pharmaceuticals shares in Q1 2025, an estimated $107.
  • Studio Investment Management first reported a position in Corbus Pharmaceuticals in Q2 2022 and held it in 11 quarters.
  • Studio Investment Management's Corbus Pharmaceuticals position peaked at $407 in Q2 2024.
  • 86 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2025.

Based on Studio Investment Management's 13F filing for Q1 2025, filed 14 May 2025.